Devalingam Mahalingam is an Oncology physician. ClinicalTrials.gov lists 11 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
645 N Michigan Ave Ste 1006
Chicago, IL 606112814
Telephone
210-413-1723Registry record last updated 21 Jul 2022.
Clinical trials
- BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
Sponsor: Northwestern University
- Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
Sponsor: Devalingam Mahalingam
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202511 payments$21,185openpaymentsdata.cms.gov ↗
- Exelixis Inc.Program year20259 payments
- Eli Lilly and CompanyProgram year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
69.9%CD38-directed Cytolytic Antibody22.9%Daratumumab100%Part B, office-administered≥34 patientsOther monoclonal antibodies and antibody drug conjugates18.3%Teclistamab-cqyv100%Part B, office-administered≥12 patients+ 6 more classes in this area
Metabolism & gastrointestinal
12.4%Other antiemetics9.3%Fosaprepitant100%Part B, office-administered≥20 patientsSerotonin-3 Receptor Antagonist1.6%Palonosetron hcl79%Granisetron hydrochloride20%Ondansetron Odt2%Part D + Part B≥44 patients+ 1 more class in this area
Dermatology
8.3%Corticosteroid8.3%Methylprednisolone sodium succinate100%Part B, office-administered≥35 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”